Advances in Alzheimer’s disease therapeutics: biochemistry, exploring bioactive compounds and novel approaches

Abstract

The most rampant and complex form of dementia is Alzheimer’s disease (AD) which is characterized by various cognitive deficits and personality abnormalities. AD is a neurodegenerative condition marked by the buildup of beta-amyloid peptide fragments and Tau protein in the form of tangles in brain neurons. The presence of β-amyloid peptide, Tau protein, oxidative stress, and an aggravated neuro-inflammatory response are all part of its pathophysiological pathway. Quite a number of invertebrates have been genetically modified such that they express human proteins that play a role or two in the pathogenesis of AD. Also, in order to create an animal model of AD, quite a number of substances have been investigated for their potential to cause cognitive dysfunctions. The following keywords were used to search and retrieve articles from reputable databases, including Scopus, Science Direct, Google Scholar and PubMed: “Alzheimer’s Disease,” “Tau protein,” “beta-secretase,” “Cognitive Impairments,” “Amyloid beta,” “phytochemicals and AD,” “neurofibrillary tangles” and “Neurotoxins that induce AD,” The aim of this review is to advance a better understanding of the functions and roles of Tau and amyloid precursor proteins in the pathogenesis of AD; and to offer updated and recent information on the use of plant chemicals in the treatment of AD. It is expedient to state that not all biochemical, cognitive, behavioral and histological disorders are recapitulable. Nevertheless, research into the etiology of this severely debilitating disease is being aided by experimental models of AD created by chemicals and bioengineered model organisms.